Intersect ENT

Located in Menlo Park, CA, Intersect ENT’s initial focus is chronic sinusitis, a condition that affects one out of eight adults in the U.S. and has a greater impact on quality of life than congestive heart failure or chronic back pain.For these chronic sinus sufferers, their condition deeply impacts their quality of life and often requires a complex combination of medical and surgical therapy. While surgical solutions relieve symptoms in many patients, disease can recur even in the postoperative period; the majority have symptoms that persist within the first year. We at Intersect ENT believed there had to be a better way — to improve both the patient experience and surgical outcomes as well as alleviate physician frustration with disease recurrence. We developed the PROPEL steroid-releasing implant with these goals in mind. PROPEL sinus implants props open the sinus cavity following surgery and allows for localized delivery of steroid directly to the sinus mucosa, as it dissolves. For patients, this may mean less invasive treatment options, improved surgical outcomes, and reduced need for systemic drugs such as oral steroids which can lead to serious side effects. Innovation and creativity are driving forces for our company. Intersect ENT holds more than 25 issued U.S. patents and more than 90 patents and pending applications worldwide. Intersect ENT (NASDAQ: XENT) is a publicly traded company.